No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
www.bayer.comNo one on the platform currently holds BAYN.SG.
No tracked institution reports a position in BAYN.SG as of their last filing.
No one on the platform has traded BAYN.SG yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -2.2% | 1.9% | ||||
| Profit Margin % | -7.9% | -1.8% | 1.3% | |||
| Free Cash Flow Margin % | 4.6% | 6.6% | 10.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $45.8B | +0.5% | $4.53 | $2.13–$6.76 | — | 11 |
| 2027 | $47.0B | +2.7% | $4.79 | $3.51–$7.14 | — | 11 |
| 2028 | $48.6B | +3.3% | $5.34 | $4.17–$7.17 | — | 10 |
| 2029 | $49.2B | +1.3% | $5.50 | $5.29–$5.65 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.77 | $0.95 | +23.5% |
| 2026-05-12 | $2.31 | $2.71 | +17.3% |
| 2026-03-04 | $0.39 | $0.62 | +60.7% |
| 2025-11-12 | $0.37 | $0.57 | +55.7% |
| 2025-08-06 | $0.90 | $1.23 | +37.0% |
| 2025-05-13 | $2.32 | $2.49 | +7.3% |
| 2025-03-05 | $0.99 | $1.05 | +6.2% |
| 2024-11-12 | $0.31 |
| $0.24 |
| -23.7% |
| +0.56% |
| $10.6B |
| — |
| FRE.DEFresenius SE & Co. KGaA | $45.39 | -0.69% | $25.6B | — |
| GE9.FGenmab A/S | $292.00 | +3.88% | $18.0B | — |
Source: Financial Modeling Prep · peers by sector/industry